Sandoz

Pioneering access to medicines for patients globally is the stated purpose that defines Sandoz, recognised as the global leader in generic and biosimilar medicines. Operating at the intersection of affordability and clinical complexity, the company focuses on bringing established therapeutic options within reach of patients across international markets.

Generic medicines form one pillar of the Sandoz portfolio. By developing high-quality equivalents of off-patent compounds, the company supports healthcare systems in managing cost pressures without compromising on treatment standards. This work spans a broad range of therapy areas, enabling prescribers and payers to expand access at scale.

The biosimilar medicines division reflects the company's commitment to the more technically demanding end of the generics sector. Biosimilars require complex biological manufacturing processes and rigorous comparability studies, and Sandoz positions itself as a leader in meeting these standards. As biologic therapies continue to represent a growing share of healthcare spending, the ability to deliver credible biosimilar alternatives carries significant value for health systems worldwide.

Together, the generics and biosimilars businesses underpin a model oriented towards broadening the availability of proven treatments. For industry professionals, partners, and healthcare stakeholders seeking a counterpart with global reach in off-patent and biological medicines, Sandoz represents one of the most established names in the sector.

Further information is available at sandoz.com.